Inventiva is burning cash at approximately 3,000% of revenue — an extreme rate — and its market capitalization of roughly $890 million falls below the $1 billion minimum threshold that defines the investable universe for this strategy, removing it from consideration. RSI at 18 and a falling-knife technical setup compound the risk, though the long-term moving average slope remains positive, suggesting the selloff may not yet have found a durable floor.
Thesis pillars
- Extreme Cash Burn Vs Revenue→Stable
- Below Minimum Market Cap Floor→Stable
- Capitulation Level Rsi Ambiguous Trend→Stable
- +1 more pillar — see the Why tab for full reasoning
Inventiva S.A. - American Depos (IVA) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $3.52, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $15.13 vs price $3.52 — ratio 4.3×). Rejected, falling back to technical TP.; Market cap $0.81B below $1B minimum.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a... Read more
Hold if already holding. Not a fresh buy at $3.52, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $15.13 vs price $3.52 — ratio 4.3×). Rejected, falling back to technical TP.; Market cap $0.81B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.81B below $1B minimum. Not in investable universe. Score 5.0/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 88d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-29Recent Developments — Inventiva S.A. - American Depos
Latest news
- NEWS Inventiva Secures €43M Investment for Liver Disease Drug, Supports Phase 3 MASH Treatment Trial — benzinga Jun 16, 2026
- NEWS Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session — benzinga Jun 10, 2026
- NEWS Inventiva Enters Comprehensive Refinancing Agreements, Comprising Repayment Of The Existing EIB Loan And Partial Warrant — benzinga Jun 2, 2026
- NEWS Inventiva Halts Paris Trading Ahead of Planned Financing Announcement, Shares Expected to Resume Trading Later Tuesday — benzinga Jun 2, 2026
- NEWS Inventiva Recruits Axel-Sven Malkomes As New CFO — benzinga Apr 22, 2026 neutral
Generated 2026-06-30T00:04:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $3.52, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $15.13 vs price $3.52 — ratio 4.3×). Rejected, falling back to technical TP.; Market cap $0.81B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.81B below $1B minimum. Not in investable universe. Target $4.86 (+38.1%), stop $3.28 (−7.3%), A.R:R 0.0:1. Score 5.0/10, moderate confidence.
Take-profit target: $4.86 (+37.9% upside). Target $4.86 (+38.1%), stop $3.28 (−7.3%), A.R:R 0.0:1. Stop-loss: $3.28.
DATA_ISSUE: analyst_target_implausible (raw $15.13 vs price $3.52 — ratio 4.3×). Rejected, falling back to technical TP.; Market cap $0.81B below $1B minimum.
Inventiva S.A. - American Depos trades at a P/E of N/A (forward -3.9). TrendMatrix value score: 5.0/10. Verdict: Hold.
16 analysts cover IVA with a consensus score of 4.4/5. Average price target: $15.
What does Inventiva S.A. - American Depos do?Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies...
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.